Skip to content
sellWeak cluster of 310b5-1 plan

Pamela J. Cramer sold $586k of RYTM

Chief Human Resources Officer at RHYTHM PHARMACEUTICALS, INC.. 9,375 shares at an average of $62.50, traded Nov 6, 2024, filed Nov 8, 2024.

Warning score
34
Value
$586k
9,375 shares
Holdings after
13,500
-52% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet

Score components

  • Role
    Officer
    +15
  • Trade size
    $586k at market
    +19
  • Share of holdings sold
    Sold 52% of holdings
    +20
  • Cluster
    3 insiders selling within 14 days
    +15
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

This signal so far: 1m -12.5%, 3m -12.1%, 6m -14.8%.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

RYTMOct 9, 2026 · close 90.78
Since filing Nov 8, 2024: +34.8%SPY +33.2% · excess +1.7%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001104659-24-115867, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Nov 6, 2024MOption exercise
Common Stock10b5-1
+4,687$19.02$89k18,187Nov 8, 2024
Nov 6, 2024SOpen-market sale
Common Stock10b5-1
-4,687$60.00$281k13,500Nov 8, 2024
Nov 7, 2024MOption exercise
Common Stock10b5-1
+4,688$19.02$89k18,188Nov 8, 2024
Nov 7, 2024SOpen-market sale
Common Stock10b5-1
-4,688$65.00$305k13,500Nov 8, 2024
Nov 6, 2024MOption exercise
Stock Options (Right to buy)derivative10b5-1
-4,687$0.00$018,750Nov 8, 2024
Nov 7, 2024MOption exercise
Stock Options (Right to buy)derivative10b5-1
-4,688$0.00$014,062Nov 8, 2024

Related signals

Other insiders at RHYTHM PHARMACEUTICALS, INC. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
28Weak
RYTMsell 210b5-1
RHYTHM PHARMACEUTICALS, INC.
David P Meeker
President and CEO
$5.1M
50,000 shares
-17%
30Weak
RYTMsell 210b5-1
RHYTHM PHARMACEUTICALS, INC.
Hunter C Smith
Chief Financial Officer
$6.6M
62,774 shares
-36%
38Weak
RYTMsell
RHYTHM PHARMACEUTICALS, INC.
Christopher Paul German
Corporate Controller & CAO
$503k
5,614 shares
-97%
24Weak
RYTMsell10b5-1
RHYTHM PHARMACEUTICALS, INC.
Hunter C Smith
Chief Financial Officer
$806k
7,954 shares
-7%
23Weak
RYTMsell10b5-1
RHYTHM PHARMACEUTICALS, INC.
Hunter C Smith
Chief Financial Officer
$709k
7,071 shares
-6%
23Weak
RYTMsell10b5-1
RHYTHM PHARMACEUTICALS, INC.
Hunter C Smith
Chief Financial Officer
$703k
6,628 shares
-5%
0Weak
RYTMsell10b5-1
RHYTHM PHARMACEUTICALS, INC.
Pamela J. Cramer
Chief Human Resources Officer
$372k
3,350 shares
-14%
0Weak
RYTMsell10b5-1
RHYTHM PHARMACEUTICALS, INC.
Pamela J. Cramer
Chief Human Resources Officer
$352k
3,350 shares
-14%
33Weak
RYTMsell 210b5-1
RHYTHM PHARMACEUTICALS, INC.
Pamela J. Cramer
Chief Human Resources Officer
$2.3M
22,866 shares
-57%
33Weak
RYTMsell 210b5-1
RHYTHM PHARMACEUTICALS, INC.
Joseph Shulman
Chief Technical Officer
$1.1M
9,748 shares
-53%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Pamela J. Cramer sold $586k of RYTM | InsiderTell